Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.

Basit Öğe Kaydı
dc.authorid0000-0002-4075-6692en_US
dc.contributor.authorKaragöz, B.
dc.contributor.authorSüleymanoğlu, S.
dc.contributor.authorUzun, G.
dc.contributor.authorBilgi, O.
dc.contributor.authorAydınöz, S.
dc.contributor.authorHaholu, A.
dc.contributor.authorÖnem, Y.
dc.contributor.authorKandemir, E. G.
dc.date.accessioned2024-07-12T21:02:06Z
dc.date.available2024-07-12T21:02:06Z
dc.date.issued2008en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractAbstract: The current use of doxorubicin is regarded as an absolute contraindication for hyperbaric oxygen (HBO2) therapy because of the increased risk of cardiotoxicity. The aim of this study was to investigate whether additional exposure to HBO2 during the course of doxorubicin treatment would further increase the cardiotoxicity of doxorubicin in rats. Female Wistar rats were treated with either HBO2 (n = 10) or doxorubicin (n = 8) or a combination of both treatments (n = 10) for 4 consecutive weeks and followed up for an additional 4 weeks. Cardiomyopathy was evaluated using two-dimensional and M-mode echocardiography at baseline, at the fourth, sixth and eighth weeks, and by histopathological investigation of the rat hearts at the eighth week. Doxorubicin treatment significantly reduced ejection fraction and fractional shortening (P < 0.001) and caused severe histopathological injury (P < 0.05) indicating development of cardiotoxicity. Although the combination of doxorubicin and HBO2 also markedly reduced ejection fraction and fractional shortening (P < 0.001), this reduction was significantly less than that of doxorubicin treatment (P < 0.05). HBO2 therapy also attenuated doxorubicin-induced histopathological changes in rat hearts (P < 0.05). HBO2 alone did not alter echocardiographic parameters or histopathological findings (P > 0.05). In conclusion, HBO2 therapy does not potentiate doxorubicin-induced cardiotoxicity in rats. Cardioprotection conferred by HBO2 against doxorubicin warrants further investigation.en_US
dc.identifier.citationKaragoz, B., Suleymanoglu, S., Uzun, G., Bilgi, O., Aydinoz, S., Haholu, A., Turken, O., Onem, Y. ve Kandemir, E.G. (2008). Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 102(3), s. 287-92.en_US
dc.identifier.endpage292en_US
dc.identifier.issn1742-7843
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage287en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/j.1742-7843.2007.00196.x
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3580
dc.identifier.volume102en_US
dc.institutionauthorTürken, Orhan
dc.language.isoenen_US
dc.publisherWiley Online Libraryen_US
dc.relation.ispartofBCPTen_US
dc.relation.isversionof10.1111/j.1742-7843.2007.00196.xen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00407
dc.titleHyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu